July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Outcomes Based on Baseline (BL) Features of Choroidal Neovascularization (CNV) in Patients (pts) with Neovascular Age-related Macular Degeneration (nAMD): Post-hoc Analysis from the VIEW Studies
Author Affiliations & Notes
  • Nathan Steinle
    California Retina Consultants, Arroyo Grande, California, United States
  • Diana V Do
    Stanford University, Palo Alto, California, United States
  • Desmond Thompson
    Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
  • Andrea Gibson
    Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
  • Namrata Saroj
    Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States
  • Footnotes
    Commercial Relationships   Nathan Steinle, Alimera Sciences (C), Almiera Sciences (R), Genentech (R), Genentech (F), Genentech, Inc. (C), Notal Vision (R), Regenerative Patch Technologies (C), Regeneron (C), Regeneron (R), Regeneron (F), Vortex Surgical (C), Zeiss (F); Diana Do, Genentech (F), Genentech (C), Regeneron Pharmaceuticals, Inc. (F), Santen (F), Santen (C); Desmond Thompson, Regeneron Pharmaceuticals, Inc. (E); Andrea Gibson, Regeneron Pharmaceuticals, Inc. (E); Namrata Saroj, Regeneron Pharmaceuticals, Inc. (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1619. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nathan Steinle, Diana V Do, Desmond Thompson, Andrea Gibson, Namrata Saroj; Outcomes Based on Baseline (BL) Features of Choroidal Neovascularization (CNV) in Patients (pts) with Neovascular Age-related Macular Degeneration (nAMD): Post-hoc Analysis from the VIEW Studies. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1619.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To assess visual outcomes of pts with nAMD by BL features of CNV during the first year (BL–week (wk) 52) of VIEW studies.

Methods : Pts with nAMD (n=2457) were randomized to receive one of the following treatments from BL to wk 52: 0.5 mg intravitreal ranibizumab q4 wks, 2 mg intravitreal aflibercept injection (IAI) q4 wks, 0.5 mg IAI q4 wks, or 2 mg IAI q8 wks after 3 monthly injections. Using Kaplan-Meier methodology, cumulative incidences of the first sustained (≥2 consecutive occurrences) gain of ≥15 letters and loss of >5 letters were assessed in pooled treatment groups in an integrated analysis of the VIEW studies by quartiles (Q) of BL CNV area (Q1: <3.12, Q2: ≥3.12-<6.00, Q3: ≥6.00-<10.08, Q4: ≥10.08 mm2) and CNV type (occult, minimally classic [MC], predominantly classic [PC]).

Results : There were 596, 603, 598, and 602 pts in Q1–Q4, respectively. By wk 52, corresponding cumulative incidences of the first sustained gain of ≥15 letters were 46.5%, 39.2%, 32.1%, and 31.8%, respectively. Similarly, cumulative incidences of the first sustained loss of >5 letters were 8.9%, 12.2%, 21.5%, and 22.0% in Q1–Q4, respectively. There were 924, 837, 629 pts with occult, MC and PC lesions, respectively. Corresponding cumulative incidences of the first sustained gain of >15 letters were 32.3%, 37.5%, and 45.5%. Similarly, cumulative incidences of the first sustained loss of >5 letters were 14.3%, 17.4%, and 17.4%, respectively. Relative risks of the first sustained gain of ≥15 letters and loss of >5 letters from baseline by baseline CNV size and type are shown in Table.

Conclusions : These data suggest that, with increasing BL CNV area, cumulative incidence of the first sustained ≥15 letters gain decreased and cumulative incidence of >5 letters loss increased in a non-linear manner for both visual acuity outcomes. The lowest cumulative incidence of the first sustained >15 letters gain and >5 letters loss was seen amongst pts with occult lesions.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×